Growth Capital For Life Sciences & Healthcare
Telegraph Hill Partners is a venture capital firm dedicated to helping life science, medical device and healthcare companies achieve their growth objectives. When you work with us, you get an experienced team that knows how to drive growth and profitability while maintaining the vision and integrity of the organization.
We seek to partner with innovative companies by providing capital and strategic guidance to help them grow.
Latest News & Announcements
CanSino Biologics and Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine
- CanSinoBIO will license in Precision NanoSystems’ proprietary RNA vaccine platform technology - Precision NanoSystems will lead RNA vaccine formulation development - CanSinoBIO will lead COVID-19 antigen design, pre-clinical testing and clinical trials Tianjin, China and Vancouver, Canada – CanSin [...]
Nivagen Pharmaceuticals Closes $16 Million Growth Equity Financing from Telegraph Hill Partners
Additional Resources Will Support Product Development and Expansion of Manufacturing Capabilities Sacramento, Calif.—(May 19, 2020)—Nivagen Pharmaceuticals, Inc. (“Nivagen”), a specialty pharmaceuticals company, announced the closing of a $16 million equity financing round led by Telegraph Hill Pa [...]
Nimble announces collaboration to discover and develop novel peptide-based compounds for SARS-CoV-2 diagnostics
MADISON, WI--Nimble Therapeutics, Inc. today announced a collaboration with Roche Diagnostics to accelerate discovery of novel peptide-based molecules for the development of SARS-CoV-2 in vitro diagnostic assays. Nimble will extend its proprietary peptide synthesis, screening and optimization platfo [...]